Physician profile
Abhijit A Raval
NPI 1508052275
$1,977,602.96
in general payments reported to CMS, 2019-2025
60 companies · $423K in 2025
The $423K reported for 2025 was more than what 99% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $255K · 2020: $187K · 2021: $216K · 2022: $255K · 2023: $312K · 2024: $331K · 2025: $423K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $789K · Education: $147K · Travel and Lodging: $61K · Consulting Fee: $47K · Food and Beverage: $23K · Gift: $40.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $788,960.93 |
| Education | $146,752.57 |
| Travel and Lodging | $60,515.26 |
| Consulting Fee | $46,856.00 |
| Food and Beverage | $22,688.73 |
| Gift | $40.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $313,000.18 | 2019-2025 | Uptravi, Opsumit |
| United Therapeutics Corporation | $291,843.40 | 2019-2025 | Tyvaso, Remodulin, Orenitram |
| Glaxosmithkline, LLC. | $264,335.67 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Genzyme Corporation | $203,040.13 | 2023-2025 | |
| Intuitive Surgical, INC. | $162,266.51 | 2019-2025 | Da Vinci Surgical System, Ion |
| Astrazeneca Pharmaceuticals Lp | $152,086.07 | 2019-2025 | Breztri, Andexxa, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $141,930.52 | 2019-2025 | Ofev |
| Insmed, INC. | $116,638.96 | 2019-2025 | Arikayce, Brinsupri |
| Mylan Specialty L.P. | $78,521.27 | 2019-2024 | Yupelri, Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $78,417.50 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $57,673.34 | 2020-2025 | Acthar |
| Merck Sharp & Dohme LLC | $40,853.11 | 2019-2025 | Winrevair, Keytruda |
| Regeneron Healthcare Solutions, INC. | $23,621.74 | 2024-2025 | Dupixent |
| Johnson & Johnson Health Care Systems INC. | $20,317.21 | 2023-2025 | Veletri, Opsumit, Uptravi |
| Viatris Specialty LLC | $10,801.77 | 2025 | Yupelri |
Show all 54 companies
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abhijit Raval listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.